106 related articles for article (PubMed ID: 29985803)
1. Impact of Protease Inhibitors on HIV-Associated Kaposi Sarcoma Incidence: A Systematic Review.
Chang E; Mapakshi SR; Mbang P; El-Mallawany NK; Kramer JR; White DL; Chiao EY
J Acquir Immune Defic Syndr; 2018 Oct; 79(2):141-148. PubMed ID: 29985803
[TBL] [Abstract][Full Text] [Related]
2. Incident Kaposi sarcoma during the expansion of antiretroviral therapy eligibility in Nigeria: a retrospective cohort study.
Akanbi MO; Bilaver LA; Achenbach C; Hirschhorn LR; Rivera AS; Adekolujo OS; Adekola KUA; Silas OA; Agaba PA; Agbaji O; Shehu NY; Sagay SA; Hou L; Murphy RL
BMC Cancer; 2023 Sep; 23(1):890. PubMed ID: 37735371
[TBL] [Abstract][Full Text] [Related]
3. Antiretroviral therapy and Kaposi's sarcoma trends and outcomes among adults with HIV in Latin America.
Castilho JL; Kim A; Jenkins CA; Grinsztejn B; Gotuzzo E; Fink V; Padgett D; Belaunzaran-Zamudio PF; Crabtree-Ramírez B; Escuder MM; Souza RA; Tenore SB; Pimentel SR; Ikeda MLR; de Alencastro PR; Tupinanbas U; Brites C; Luz E; Netto J; Cortes CP; Grangeiro A; Shepherd BE; McGowan CC;
J Int AIDS Soc; 2021 Jan; 24(1):e25658. PubMed ID: 33405281
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study.
AIDS-defining Cancer Project Working Group for IeDEA and COHERE in EuroCoord
Clin Infect Dis; 2017 Oct; 65(8):1316-1326. PubMed ID: 28531260
[TBL] [Abstract][Full Text] [Related]
5. Changing Incidence and Risk Factors for Kaposi Sarcoma by Time Since Starting Antiretroviral Therapy: Collaborative Analysis of 21 European Cohort Studies.
Cancer Project Working Group for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study in EuroCoord
Clin Infect Dis; 2016 Nov; 63(10):1373-1379. PubMed ID: 27535953
[TBL] [Abstract][Full Text] [Related]
6. A prospective cohort study identifies two types of HIV+ Kaposi Sarcoma lesions: proliferative and inflammatory.
Moorad R; Kasonkanji E; Gumulira J; Gondwe Y; Dewey M; Pan Y; Peng A; Pluta LJ; Kudowa E; Nyasosela R; Tomoka T; Tweya H; Heller T; Gugsa S; Phiri S; Moore DT; Damania B; Painschab M; Hosseinipour MC; Dittmer DP
Int J Cancer; 2023 Dec; 153(12):2082-2092. PubMed ID: 37602960
[TBL] [Abstract][Full Text] [Related]
7. Extracutaneous Kaposi sarcoma risk remains higher in people with HIV in the post-ART era.
Dinh S; Malmström S; Möller IK; Yilmaz A; Svedhem V; Carlander C
AIDS; 2023 Nov; 37(13):2041-2048. PubMed ID: 37451428
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the safety of nivolumab in people living with HIV with advanced cancer on antiretroviral therapy: the AIDS Malignancy Consortium 095 Study.
Rajdev L; Jackie Wang CC; Joshi H; Lensing S; Lee J; Ramos JC; Baiocchi R; Ratner L; Rubinstein PG; Ambinder R; Henry D; Streicher H; Little RF; Chiao E; Dittmer DP; Einstein MH; Cesarman E; Mitsuyasu R; Sparano JA;
Cancer; 2024 Mar; 130(6):985-994. PubMed ID: 37962072
[TBL] [Abstract][Full Text] [Related]
9. Impact of Kaposi Sarcoma on Quality of Life Amongst HIV-infected Adults Initiating Antiretroviral Therapy in East Africa.
Scott L; Laker-Oketta M; Byakwaga H; Glidden D; Mwebesa B; Muzoora C; Maurer T; Assenzio M; Hunt P; Bangsberg D; Haberer J; Martin J
medRxiv; 2023 Jul; ():. PubMed ID: 37546765
[TBL] [Abstract][Full Text] [Related]
10. Kaposi Sarcoma Incidence, Burden, and Prevalence in United States People with HIV, 2000-2015.
Peprah S; Engels EA; Horner MJ; Monterosso A; Hall HI; Johnson AS; Pfeiffer RM; Shiels MS
Cancer Epidemiol Biomarkers Prev; 2021 Sep; 30(9):1627-1633. PubMed ID: 34162660
[TBL] [Abstract][Full Text] [Related]
11. Feasibility of Rapid Case Ascertainment for Cancer in East Africa: An Investigation of Community-Representative Kaposi Sarcoma in the Era of Antiretroviral Therapy.
Semeere A; Byakwaga H; Laker-Oketta M; Freeman E; Busakhala N; Wenger M; Kasozi C; Ssemakadde M; Bwana M; Kanyesigye M; Kadama-Makanga P; Rotich E; Kisuya J; Sang E; Maurer T; Wools-Kaloustian K; Kambugu A; Martin J
Cancer Epidemiol; 2021 Oct; 74():101997. PubMed ID: 34385076
[TBL] [Abstract][Full Text] [Related]
12. Clonality, Mutation and Kaposi Sarcoma: A Systematic Review.
Indave Ruiz BI; Armon S; Watanabe R; Uttley L; White VA; Lazar AJ; Cree IA
Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267506
[TBL] [Abstract][Full Text] [Related]
13. Breast cancer in women living with HIV: A first global estimate.
McCormack VA; Febvey-Combes O; Ginsburg O; Dos-Santos-Silva I
Int J Cancer; 2018 Dec; 143(11):2732-2740. PubMed ID: 29992553
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 Integrase Inhibitors That Are Broadly Effective against Drug-Resistant Mutants.
Smith SJ; Zhao XZ; Burke TR; Hughes SH
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29987149
[TBL] [Abstract][Full Text] [Related]
15. Impact of Routine Cryptococcal Antigen Screening and Targeted Preemptive Fluconazole Therapy in Antiretroviral-naive Human Immunodeficiency Virus-infected Adults With CD4 Cell Counts <100/μL: A Systematic Review and Meta-analysis.
Temfack E; Bigna JJ; Luma HN; Spijker R; Meintjes G; Jarvis JN; Dromer F; Harrison T; Cohen JF; Lortholary O
Clin Infect Dis; 2019 Feb; 68(4):688-698. PubMed ID: 30020446
[TBL] [Abstract][Full Text] [Related]
16. Extended-Duration MK-8591-Eluting Implant as a Candidate for HIV Treatment and Prevention.
Barrett SE; Teller RS; Forster SP; Li L; Mackey MA; Skomski D; Yang Z; Fillgrove KL; Doto GJ; Wood SL; Lebron J; Grobler JA; Sanchez RI; Liu Z; Lu B; Niu T; Sun L; Gindy ME
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30012772
[TBL] [Abstract][Full Text] [Related]
17. HIV RNA persists in rectal tissue despite rapid plasma virologic suppression with dolutegravir-based therapy.
Lahiri CD; Brown NL; Ryan KJ; Acosta EP; Sheth AN; Mehta CC; Ingersoll J; Ofotokun I
AIDS; 2018 Sep; 32(15):2151-2159. PubMed ID: 30005011
[TBL] [Abstract][Full Text] [Related]
18. Determinants of high-grade anal intraepithelial lesions in HIV-positive MSM.
Clifford GM; Siproudhis L; Piroth L; Poizot-Martin I; Radenne S; Reynes J; Lesage A; Heard I; Henno S; Fléjou JF; Marchand L; Combes JD; Etienney I;
AIDS; 2018 Oct; 32(16):2363-2371. PubMed ID: 30005009
[TBL] [Abstract][Full Text] [Related]
19. Comparison of 48-week efficacies of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide and nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimens: a systematic review and network meta-analysis.
Gallien S; Massetti M; Flandre P; Leleu H; Descamps D; Lazaro E
HIV Med; 2018 Jul; ():. PubMed ID: 30004176
[TBL] [Abstract][Full Text] [Related]
20. Pregnancy outcomes and infant growth among babies with in-utero exposure to tenofovir-based preexposure prophylaxis for HIV prevention.
Heffron R; Mugo N; Hong T; Celum C; Marzinke MA; Ngure K; Asiimwe S; Katabira E; Bukusi EA; Odoyo J; Tindimwebwa E; Bulya N; Baeten JM;
AIDS; 2018 Jul; 32(12):1707-1713. PubMed ID: 30001244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
